| 1 |
Lass-Flörl C, Steixner S. The changing epidemiology of fungal infections [J]. Mol Aspects Med, 2023, 94: 101215.
|
| 2 |
Vallabhaneni S, Benedict K, Derado G, et al. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013 [J]. Open Forum Infect Dis, 2017, 4(1): ofw268.
|
| 3 |
Li ZT, Li YM, Chen YJ, et al. Trends of pulmonary fungal infections from 2013 to 2019: an AI-based real-world observational study in Guangzhou, China [J]. Emerg Microbes Infect, 2021, 10(1): 450-460.
|
| 4 |
Vincent JL, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017 [J]. JAMA, 2020, 323(15): 1478-1487.
|
| 5 |
Denning DW. Global incidence and mortality of severe fungal disease [J]. Lancet Infect Dis, 2024, 24(7): e428-e438.
|
| 6 |
Kang JS. Changing trends in the incidence and clinical features of pneumonia in non-HIV patients before and during the COVID-19 era and risk factors for mortality between 2016 and 2022 [J]. Life (Basel), 2023, 13(6): 1335.
|
| 7 |
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India [J]. Emerg Infect Dis, 2021, 27(9): 2349-2359.
|
| 8 |
Brown GD, Denning DW, Gow NA, et al. Hidden kllers: human fungal infections [J]. Sci Transl Med, 2012, 4(165): 165rv13.
|
| 9 |
Mansoor S, Ahmed TI, Happa K, et al. Spectrum of mucormycosis before and during COVID-19: epidemiology, diagnosis, and current therapeutic interventions [J]. Curr Fungal Infect Rep, 2022, 16(4): 131-142.
|
| 10 |
Lin CY, Liu WL, Chang CC, et al. Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes [J]. Ann Intensive Care, 2017, 7(1): 9.
|
| 11 |
Zhu XJ, Ge YY, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases [J]. Virus Res, 2020, 285: 198005.
|
| 12 |
Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology [J]. Clin Microbiol Infect, 2022, 28(4): 580-587.
|
| 13 |
Bassetti M, Azoulay E, Kullberg B-J, et al. EORTC/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group [J]. Clin Infect Dis, 2021, 72(Suppl 2): S121-S127.
|
| 14 |
Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India [J]. Lancet Infect Dis, 2022, 22(9): e240-e253.
|
| 15 |
Chen NS, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223): 507-513.
|
| 16 |
Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study [J]. Lancet Respir Med, 2022, 10(2): 180-190.
|
| 17 |
Permpalung N, Chiang TP-Y, Massie AB, et al. Coronavirus disease 2019-associated pulmonary aspergillosis in mechanically ventilated patients [J]. Clin Infect Dis, 2022, 74(1): 83-91.
|
| 18 |
Harrigan JJ, Abdallah HO, Clarke EL, et al. Respiratory microbiome disruption and risk for ventilator-associated lower respiratory tract infection [J]. Clin Infect Dis, 2022, 74(9): 1564-1571.
|
| 19 |
Kayaaslan B, Eser F, Kaya Kalem A, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients [J]. Mycoses, 2021, 64(9): 1083-1091.
|
| 20 |
Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections [J]. Lancet, 2003, 362(9398): 1828-1838.
|
| 21 |
Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001-2010 [J]. Emerg Infect Dis, 2014, 20(7): 1149-1155.
|
| 22 |
White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit [J]. Clin Infect Dis, 2021, 73(7): e1634-e1644.
|
| 23 |
Li H, Liu L, Zhang DY, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses [J]. Lancet, 2020, 395(10235): 1517-1520.
|
| 24 |
Henao-Martínez AF, Corbisiero MF, Salter I, et al. Invasive pulmonary aspergillosis real-world outcomes: clinical features and risk factors associated with increased mortality [J]. Med Mycol, 2023, 61(8): myad074.
|
| 25 |
Kariyawasam RM, Dingle TC, Kula BE, et al. Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis [J]. Clin Microbiol Infect, 2022, 28(7): 920-927.
|
| 26 |
Kula BE, Clancy CJ, Nguyen MH, et al. Invasive mould disease in fatal COVID-19: a systematic review of autopsies [J]. Lancet Microbe, 2021, 2(8): e405-e414.
|
| 27 |
Pasquier G, Bounhiol A, Robert Gangneux F, et al. A review of significance of aspergillus detection in airways of ICU COVID-19 patients [J]. Mycoses, 2021, 64(9): 980-988.
|
| 28 |
Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries [J]. Lancet Microbe, 2022, 3(7): e543-e552.
|
| 29 |
Loh JT, Lam KP. Fungal infections: immune defense, immunotherapies and vaccines [J]. Adv Drug Deliv Rev, 2023, 196: 114775.
|
| 30 |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor [J]. Cell, 2020, 181(2): 271-280.
|
| 31 |
Dewi IMW, Janssen NaF, Rosati D, et al. Invasive pulmonary aspergillosis associated with viral pneumonitis [J]. Curr Opin Microbiol, 2021, 62: 21-27.
|
| 32 |
Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis [J]. Nat Biotechnol, 2020, 38(8): 970-979.
|
| 33 |
Bertuzzi M, Hayes GE, Icheoku UJ, et al. Anti-aspergillus activities of the respiratory epithelium in health and disease [J]. J Fungi (Basel), 2018, 4(1): 8.
|
| 34 |
Liu H, Lee MJ, Solis NV, et al. Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion [J]. Nat Microbiol, 2016, 2: 16211.
|
| 35 |
Salazar F, Bignell E, Brown GD, et al. Pathogenesis of respiratory viral and fungal coinfections [J]. Clin Microbiol Rev, 2022, 35(1): e0009421.
|
| 36 |
Dorward DA, Russell CD, Um IH, et al. Tissue-specific immunopathology in fatal COVID-19 [J]. Am J Respir Crit Care Med, 2021, 203(2): 192-201.
|
| 37 |
Laforge M, Elbim C, Frère C, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19 [J]. Nat Rev Immunol, 2020, 20(9): 515-516.
|
| 38 |
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages [J]. Nat Rev Immunol, 2020, 20(6): 355-362.
|
| 39 |
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion [J]. Nat Rev Immunol, 2015, 15(8): 486-499.
|
| 40 |
Schwartz MD, Emerson SG, Punt J, et al. Decreased naive T-cell production leading to cytokine storm as cause of increased COVID-19 severity with comorbidities [J]. Aging Dis, 2020, 11(4): 742-745.
|
| 41 |
Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 [J]. Nature, 2020, 584(7821): 463-469.
|
| 42 |
Qin C, Zhou LQ, Hu ZW, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China [J]. Clin Infect Dis, 2020, 71(15): 762-768.
|
| 43 |
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type Ⅰ interferon activity and inflammatory responses in severe COVID-19 patients [J]. Science, 2020, 369(6504): 718-724.
|
| 44 |
Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006 [J]. Emerg Infect Dis, 2009, 15(9): 1395-1401.
|
| 45 |
John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis [J]. J Fungi (Basel), 2021, 7(4): 298.
|
| 46 |
Elezagic D, Johannis W, Burst V, et al. Venous blood gas analysis in patients with COVID-19 symptoms in the early assessment of virus positivity [J]. J Lab Med, 2021, 45(1): 27-30.
|
| 47 |
Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective observational cohort study [J]. Respir Res, 2020, 21(1): 276.
|
| 48 |
Gebremariam T, Lin L, Liu MF, et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis [J]. J Clin Invest, 2016, 126(6): 2280-2294.
|
| 49 |
Armstrong-James D, Youngs J, Bicanic T, et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis [J]. Eur Respir J, 2020, 56(4): 2002554.
|
| 50 |
Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review [J]. J Hosp Infect, 2021, 113: 115-129.
|
| 51 |
Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study [J]. Lancet Respir Med, 2018, 6(10): 782-792.
|
| 52 |
Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance [J]. Lancet Infect Dis, 2021, 21(6): e149-e162.
|
| 53 |
Bassetti M, Giacobbe DR, Agvald-Ohman C, et al. Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM [J]. Intensive Care Med, 2024, 50(4): 502-515.
|
| 54 |
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium [J]. Clin Infect Dis, 2020, 71(6): 1367-1376.
|
| 55 |
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis [J]. JAMA, 2020, 324(13): 1330-1341.
|
| 56 |
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19 [J]. N Engl J Med, 2021, 384(8): 693-704.
|
| 57 |
薛明, 陈辉, 谢剑锋, 等. 激素治疗能够降低重症COVID-19患者病死率? 结论尚早 [J/OL]. 中华重症医学电子杂志, 2021, 7(3): 204-207.
|
| 58 |
Chen H, Xie JF, Su N, et al. Corticosteroid therapy is associated with improved outcome in critically ill patients with COVID-19 with hyperinflammatory phenotype [J]. Chest, 2021, 159(5): 1793-1802.
|
| 59 |
Mulakavalupil B, Vaity C, Joshi S, et al. Absence of case of mucormycosis (March 2020-May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit [J]. Diabetes Metab Syndr, 2021, 15(4): 102169.
|